Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891446 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT03891446 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 455 participants, above the 270-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03891446, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Bimatoprost SR
Study Locations (20)
California
- Angeles Eye Institute /ID# 250397 - Culver City
- Duplicate_Lakeside Vision Center /ID# 240204 - Irvine
- Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240196 - La Jolla
- The Eye Research Foundation /ID# 240186 - Newport Beach
- North Bay Eye Associates Inc. /ID# 248912 - Petaluma
- Duplicate_Martel Eye Medical Group /ID# 240291 - Rancho Cordova
- The Clinical Trials Network (CTNx) /ID# 240284 - Redding
- Sacramento Eye Consultants /ID# 240263 - Sacramento
- Pacific Eye Associates /ID# 240234 - San Francisco
- Wolstan & Goldberg Eye Associates /ID# 240221 - Torrance
Arizona
- Arizona Eye Center - West Ray Road /ID# 240239 - Chandler
- Arizona Glaucoma Specialists /ID# 240212 - Phoenix
- M&M Eye Institute /ID# 240236 - Prescott
- Horizon Eye Specialists & Lasik Centers /ID# 240255 - Sun City
Florida
- Specialty Retina Center /ID# 240254 - Coral Springs
- Nature Coast Clinical Research - Crystal River /ID# 240334 - Crystal River
- Bruce Segal, MD /ID# 240292 - Delray Beach
- Eye Associates of Fort Meyers /ID# 240218 - Fort Myers
Alabama
- Trinity Research Group /ID# 240190 - Dothan
Colorado
- Colorado Eye Institute /ID# 248910 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891446
The ClinicalTrials.gov registry entry for NCT03891446 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 270-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (69% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT03891446 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03891446 about?
NCT03891446 is a clinical study titled "Long-term Safety and Efficacy Extension Trial of Bimatoprost SR". This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercia...
What is the current status of trial NCT03891446?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2019-03-27. Estimated completion is 2026-08.
What conditions does trial NCT03891446 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT03891446?
The interventions under investigation include: Standard of Care (OTHER), Bimatoprost SR (DRUG).
Who is sponsoring clinical trial NCT03891446?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03891446 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.